S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Invest in Brooklyn Gin: Hot craft spirits opportunity (Ad)pixel
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks

Eiger BioPharmaceuticals - EIGR Stock Forecast, Price & News

$1.40
+0.03 (+2.19%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.39
$1.48
50-Day Range
$1.02
$4.54
52-Week Range
$0.96
$10.02
Volume
601,858 shs
Average Volume
591,398 shs
Market Capitalization
$61.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.33

Eiger BioPharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
281.0% Upside
$5.33 Price Target
Short Interest
Healthy
2.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
1.62mentions of Eiger BioPharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$71,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.28) to ($1.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.87 out of 5 stars

Medical Sector

185th out of 1,048 stocks

Biological Products, Except Diagnostic Industry

28th out of 168 stocks


EIGR stock logo

About Eiger BioPharmaceuticals (NASDAQ:EIGR) Stock

Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Stock News Headlines

Become an Investor in Brooklyn Gin
Award winning super-premium craft gin and upcoming Brooklyn distillerypixel
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Eiger BioPharmaceuticals Announces Leadership Change
Eiger BioPharmaceuticals' Debt Overview
See More Headlines
Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Company Calendar

Last Earnings
11/03/2022
Today
1/26/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EIGR
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.33
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+281.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-33,920,000.00
Net Margins
-660.21%
Pretax Margin
-659.90%

Debt

Sales & Book Value

Annual Sales
$12.14 million
Book Value
$2.13 per share

Miscellaneous

Free Float
40,813,000
Market Cap
$61.70 million
Optionable
Not Optionable
Beta
1.64

Key Executives

  • David Apelian
    Chief Executive Officer & Director
  • Sriram Ryali
    Chief Financial Officer
  • Ingrid C. Choong
    Senior Vice President-Clinical Development
  • Christopher Kurtz
    Chief Technical Officer
  • Colin Hislop
    Senior VP-Clinical & Development Operations













EIGR Stock - Frequently Asked Questions

Should I buy or sell Eiger BioPharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EIGR shares.
View EIGR analyst ratings
or view top-rated stocks.

What is Eiger BioPharmaceuticals' stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month price targets for Eiger BioPharmaceuticals' stock. Their EIGR share price forecasts range from $3.00 to $9.00. On average, they predict the company's share price to reach $5.33 in the next year. This suggests a possible upside of 281.0% from the stock's current price.
View analysts price targets for EIGR
or view top-rated stocks among Wall Street analysts.

How have EIGR shares performed in 2023?

Eiger BioPharmaceuticals' stock was trading at $1.18 at the beginning of 2023. Since then, EIGR shares have increased by 18.6% and is now trading at $1.40.
View the best growth stocks for 2023 here
.

Are investors shorting Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 1,200,000 shares, a drop of 21.1% from the December 31st total of 1,520,000 shares. Based on an average trading volume of 905,700 shares, the days-to-cover ratio is currently 1.3 days.
View Eiger BioPharmaceuticals' Short Interest
.

When is Eiger BioPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our EIGR earnings forecast
.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by $0.07. The biotechnology company earned $4.02 million during the quarter, compared to analyst estimates of $3.93 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 106.48% and a negative net margin of 660.21%.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.44%), DAVENPORT & Co LLC (0.53%) and Sigma Planning Corp (0.26%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Evan Loh, Jeffrey S Glenn, Sriram Ryali and Thomas John Dietz.
View institutional ownership trends
.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $1.40.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals (NASDAQ:EIGR) has a market capitalization of $61.70 million and generates $12.14 million in revenue each year. The biotechnology company earns $-33,920,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The official website for the company is www.eigerbio.com. The biotechnology company can be reached via phone at (650) 272-6138, via email at ichoong@eigerbio.com, or via fax at 650-618-1621.

This page (NASDAQ:EIGR) was last updated on 1/27/2023 by MarketBeat.com Staff